|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
KR101995013B1
(ko)
|
2010-07-13 |
2019-07-02 |
에프. 호프만-라 로슈 아게 |
Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
|
|
EP2663312B1
(en)
*
|
2011-01-10 |
2017-10-11 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EP2688872A4
(en)
*
|
2011-03-22 |
2014-08-27 |
Merck Sharp & Dohme |
AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
|
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｒキナーゼ阻害剤として有用な化合物
|
|
BR112014015720B1
(pt)
*
|
2011-12-30 |
2020-03-17 |
Hanmi Pharm. Co., Ltd. |
Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
|
|
CN104582705A
(zh)
*
|
2012-01-10 |
2015-04-29 |
林伯士艾瑞斯公司 |
白介素-1受体相关激酶(irak)抑制剂和其用途
|
|
JP6109193B2
(ja)
*
|
2012-01-10 |
2017-04-05 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
チエノピリミジン化合物
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
US9216991B2
(en)
*
|
2012-07-10 |
2015-12-22 |
Ares Trading S.A. |
Pyrimidine pyrazolyl derivatives
|
|
CN104902959A
(zh)
|
2012-07-11 |
2015-09-09 |
林伯士艾瑞斯公司 |
Irak抑制剂和其用途
|
|
EP2872144A4
(en)
|
2012-07-11 |
2015-12-02 |
Nimbus Iris Inc |
IRAQ INHIBITOR AND USES THEREOF
|
|
US20140018361A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
PT4190786T
(pt)
|
2012-12-07 |
2025-05-29 |
Vertex Pharma |
Compostos úteis como inibidores da quinase atr
|
|
AU2014205577A1
(en)
|
2013-01-10 |
2015-05-28 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
|
JP6437452B2
(ja)
|
2013-01-14 |
2018-12-12 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
|
|
LT2945939T
(lt)
|
2013-01-15 |
2020-07-27 |
Incyte Holdings Corporation |
Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
JP2016512239A
(ja)
|
2013-03-15 |
2016-04-25 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な化合物
|
|
JP2016512816A
(ja)
*
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ａｔｒキナーゼの阻害剤として有用な化合物
|
|
EP2970286A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20160166576A1
(en)
*
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
EP3036238A1
(en)
*
|
2013-08-23 |
2016-06-29 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
|
|
EP3049086A4
(en)
|
2013-09-27 |
2017-02-22 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
CA2932757C
(en)
|
2013-12-06 |
2023-10-31 |
Vertex Pharmaceuticals Incorporated |
2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
|
|
US9908872B2
(en)
|
2013-12-13 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
AU2014361798B2
(en)
|
2013-12-13 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
KR20160115933A
(ko)
*
|
2014-01-10 |
2016-10-06 |
오리진 디스커버리 테크놀로지스 리미티드 |
Irak4 억제제로서의 인다졸 화합물
|
|
HRP20181795T1
(hr)
|
2014-01-13 |
2019-01-25 |
Aurigene Discovery Technologies Limited |
Biciklički heterociklilni derivati kao inhibitori irak4
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
HUE054784T2
(hu)
|
2014-05-23 |
2021-09-28 |
Hoffmann La Roche |
5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
|
|
KR102575125B1
(ko)
|
2014-06-05 |
2023-09-07 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 저해제로서 유용한 2-아미노-6-플루오로-n-[5-플루오로-피리딘-3-일]-피라졸로[1,5-a]피리미딘-3-카복스아미드 화합물의 방사성표지된 유도체, 상기 화합물의 제조 및 이의 다양한 고체 형태
|
|
RU2736219C2
(ru)
|
2014-06-17 |
2020-11-12 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способ лечения рака с использованием комбинации ингибиторов снк1 и atr
|
|
US9822124B2
(en)
|
2014-07-14 |
2017-11-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
KR102662215B1
(ko)
*
|
2014-11-06 |
2024-05-02 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
|
|
US20180185368A1
(en)
|
2014-11-06 |
2018-07-05 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
ES2958391T3
(es)
|
2014-11-06 |
2024-02-08 |
Bial R&D Invest S A |
Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
|
|
EP3221306B1
(en)
*
|
2014-11-20 |
2019-11-13 |
Merck Patent GmbH |
Heteroaryl compounds as irak inhibitors and uses thereof
|
|
US10040802B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of IRAK4 activity
|
|
WO2016144848A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
US10040798B2
(en)
|
2015-03-12 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of IRAK4 activity
|
|
WO2016144846A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
|
US9540347B2
(en)
|
2015-05-29 |
2017-01-10 |
Incyte Corporation |
Pyridineamine compounds useful as Pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
EA201890307A1
(ru)
*
|
2015-07-15 |
2018-10-31 |
Ориджин Дискавери Текнолоджиз Лимитед |
Индазольные и азаиндазольные соединения как ингибиторы irak-4
|
|
AR105967A1
(es)
|
2015-09-09 |
2017-11-29 |
Incyte Corp |
Sales de un inhibidor de pim quinasa
|
|
US10550070B2
(en)
|
2015-09-17 |
2020-02-04 |
City Of Hope |
PCNA inhibitors
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
WO2017059251A1
(en)
|
2015-10-02 |
2017-04-06 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
CN108473498B
(zh)
*
|
2015-12-22 |
2021-11-02 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
CA3020310A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
US10787454B2
(en)
|
2016-04-06 |
2020-09-29 |
BIAL—BioTech Investments, Inc. |
Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
KR20230104752A9
(ko)
|
2016-04-06 |
2024-11-15 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물및 의학적 장애의 치료에서의 그의 용도
|
|
WO2017192841A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
EP3452455A4
(en)
|
2016-05-05 |
2019-11-13 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
|
|
JP7164774B2
(ja)
|
2016-05-05 |
2022-11-02 |
ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ |
置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
EP3535273A1
(en)
*
|
2016-11-02 |
2019-09-11 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
US11072599B2
(en)
|
2017-02-01 |
2021-07-27 |
Biotheryx, Inc. |
Pyrazole compounds and uses thereof
|
|
JOP20180011A1
(ar)
|
2017-02-16 |
2019-01-30 |
Gilead Sciences Inc |
مشتقات بيرولو [1، 2-b]بيريدازين
|
|
US11419875B2
(en)
|
2017-03-31 |
2022-08-23 |
Aurigene Discovery Technologies Limited |
Compounds and compositions for treating hematological disorders
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
JP7256757B2
(ja)
|
2017-05-22 |
2023-04-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
処置用化合物及び組成物、並びにその使用方法
|
|
WO2018234342A1
(en)
*
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
Isoindolinone derivatives as irak4 modulators
|
|
WO2018234343A1
(en)
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
Benzofurans as irak4 modulators
|
|
EP3642204A1
(en)
*
|
2017-06-21 |
2020-04-29 |
H. Hoffnabb-La Roche Ag |
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
EP3704108B1
(en)
|
2017-10-31 |
2024-04-24 |
Curis, Inc. |
Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
WO2019107987A1
(en)
*
|
2017-11-30 |
2019-06-06 |
Hanmi Pharm. Co., Ltd. |
THIENO[3,2-d]PYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
IL277408B2
(en)
*
|
2018-04-05 |
2024-08-01 |
Merck Patent Gmbh |
Heteroaryl compounds as type ii irak inhibitors and uses thereof
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
CN110862375B
(zh)
*
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
JP7385658B2
(ja)
|
2018-10-30 |
2023-11-22 |
クロノス バイオ インコーポレイテッド |
Ｃｄｋ９活性を調節するための化合物、組成物、および方法
|
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
KR20220027196A
(ko)
*
|
2019-06-27 |
2022-03-07 |
바이오젠 엠에이 인코포레이티드 |
이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도
|
|
JP7386576B2
(ja)
|
2019-10-02 |
2023-11-27 |
カイノス・メディスン・インコーポレイテッド |
Ｎ－（１ｈ－イミダゾール－２－イル）ベンズアミド化合物および該化合物を活性成分として含む医薬組成物
|
|
EP4076520A4
(en)
|
2019-12-17 |
2024-03-27 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021198980A1
(en)
|
2020-04-04 |
2021-10-07 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
EP4223750B1
(en)
*
|
2020-09-30 |
2025-06-25 |
Asahi Kasei Pharma Corporation |
Nitrogen-containing bicyclic compounds which contain pyrimidine as interleukin 1 receptor-associated kinase 4 (irak-4) inhibitors to be used in the treatment of inflammatory or autoimmune diseases
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
TW202241891A
(zh)
|
2020-12-30 |
2022-11-01 |
美商凱麥拉醫療公司 |
Irak降解劑及其用途
|
|
JP2024506656A
(ja)
|
2021-02-15 |
2024-02-14 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ４分解剤およびその使用
|
|
KR20240004476A
(ko)
|
2021-04-08 |
2024-01-11 |
쿠리스 인코퍼레이션 |
암 치료를 위한 병용 요법
|
|
US12097261B2
(en)
|
2021-05-07 |
2024-09-24 |
Kymera Therapeutics, Inc. |
CDK2 degraders and uses thereof
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
WO2023076556A1
(en)
|
2021-10-29 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
|
JP2025504059A
(ja)
|
2022-01-31 |
2025-02-06 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋデグレーダー及びその使用
|